EuroHyp-1
Research type
Research Study
Full title
EuroHYP-1: European multicentre, randomised, phase III clinical trial of therapeutic hypothermia plus best medical treatment versus best medical treatment alone for acute ischaemic stroke
IRAS ID
82109
Contact name
Nikola Sprigg
Contact email
Sponsor organisation
Erlangen University
Research summary
This study aims to follow 500 older patients with heart failure, who have been given ivabradine as part of their heart failure medication, for six months. Over that time, changes will be evaluated in:
-their Quality of life (using validated instruments)
-their ability to do things (using a 6 minute walking test)
-their heart rate and blood pressure
-their perception of their health
-their physician's perception of their health
-any changes to their medications (including the total number of medicines prescribed)In addition to the core data, at 18 months patients' vital status and medications will be assessed.
The study will be managed as an observational non-interventional study, i.e. all treatments will be given as usual, by their usual care team, with no additional procedures that would not normally be given as part of Best Practice
REC name
North East - Newcastle & North Tyneside 2 Research Ethics Committee
REC reference
13/NE/0299
Date of REC Opinion
2 Dec 2013
REC opinion
Further Information Favourable Opinion